Objective:To systematically evaluate the efficacy and safety of osimertinib(AZD)combined with bevacizumab(BEV)as the treatment for advanced epidermal growth factor receptor(EGFR)mutant non-small cell lung cancer(NSCLC).Methods:Databases including PubMed,The cochrane library,Embase,Web of science,CNKI,VIP database,Wanfang database and China biology medicine database(CBM)were searched by computer,documents until December 2022 that met the inclusion and exclusion criteria were evaluated for quality and data extraction.Review Manager 5.4 and Stata 17.0 software were used for Meta-analysis.Results:Eleven research articles were included,involving 721 patients.The results of Meta-analysis showed that:in terms of efficacy,the objective response rate(ORR)of the experimental group(AZD combined with BEV)was better than that of the control group(AZD monotherapy),with statistical significance(P＜0.05).Progression-free survival(PFS)and disease control rate(DCR)in experimental group were slightly better than those in control group,but with no significant differences(P＞0.05).The overall survival time(OS)of experimental group was slightly shorter than control group,the difference was not statistically significant(P＞0.05).As for the safety,the incidence of Grade 3 or higher adverse events(Grade≥3 AEs)in the experimental group was significantly higher than that in the control group(P＜0.05).Further subgroup analysis showed that there were no statistical differences in ORR,PFS and OS between the two groups when different doses of BEV were given in the experimental group(P＞0.05).The DCR achieved better in experimental group than control group when the experimental group given BEV(7.5 mg·m-2)q3w(P＜0.05).There was no significant difference in the incidence of Grade≥3 AEs between the experimental group and the control group when BEV was gave for(7.5 mg·m-2)q3w(P＞0.05).Conclusion:AZD combined with BEV significantly improved ORR in patients with advanced EGFR-mutant NSCLC,but had no significant benefit in DCR,PFS,OS and increased the risk of Grade≥3 AEs.
维普
万方数据